Osiris Therapeutics, Inc. works in the field of regenerative medicine: a stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular, orthopedic and wound healing markets. Offers products in orthopedics, sports medicine and wound care, the company operates its business through two segments: Therapeutics and Biosurgery segment. The Therapeutics segment focuses on developing biologic stem cell drug candidates from readily available and non-controversial sources. Having developed the worlds first approved stem cell drug, products include Grafix, a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns; BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery; and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects. Products are offered directly to hospitals, clinics, and physician offices as well as through agents and distributors. Abchored in adult stem cell technology, focus is on the treatment and functional restoration of damaged or diseased tissues: indications in medical specialties, including oncology, cardiology, and orthopedics. In March 2019, Osiris Therapeutics was acquired by Smith & Nephew for a reported $660M
